STIEPROX SHAMPOO

Země: Kanada

Jazyk: angličtina

Zdroj: Health Canada

Aktivní složka:

CICLOPIROX OLAMINE

Dostupné s:

GLAXOSMITHKLINE INC

ATC kód:

D01AE14

INN (Mezinárodní Name):

CICLOPIROX

Dávkování:

1.5%

Léková forma:

SHAMPOO

Složení:

CICLOPIROX OLAMINE 1.5%

Podání:

TOPICAL

Jednotky v balení:

10ML/100ML

Druh předpisu:

Prescription

Terapeutické oblasti:

HYDROXYPYRIDONES

Přehled produktů:

Active ingredient group (AIG) number: 0115999002; AHFS:

Stav Autorizace:

CANCELLED POST MARKET

Datum autorizace:

2024-01-31

Charakteristika produktu

_ _
_September 08, 2014 _
_ _
_Page 1 of 23_
PRODUCT MONOGRAPH
Pr
STIEPROX
®
ciclopirox olamine (shampoo) 1.5% w/w
Topical Antifungal
GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
www.stiefel.ca
Date of Revision:
September 8, 2014
Submission Control No: 168647
_©_
_ 2014 GlaxoSmithKline Inc. All Rights Reserved _
_ _
_®_
_STIEPROX is_
_a registered trade-mark, used under license by GlaxoSmithKline Inc. _
_ _
_September 08, 2014 _
_ _
_Page 2 of 23_
TABLE OF CONTENTS
PAGE
PART I: HEALTH PROFESSIONAL INFORMATION ................................................... 3
SUMMARY PRODUCT INFORMATION
................................................................... 3
INDICATIONS AND CLINICAL USE
........................................................................
3
CONTRAINDICATIONS
...........................................................................................
3
WARNINGS AND PRECAUTIONS
............................................................................
4
ADVERSE REACTIONS
............................................................................................
5
DRUG INTERACTIONS
............................................................................................
6
DOSAGE AND ADMINISTRATION
..........................................................................
7
OVERDOSAGE
.........................................................................................................
7
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 8
STORAGE AND STABILITY
.....................................................................................
8
SPECIAL HANDLING INSTRUCTIONS
.................................................................... 8
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 8
PART II: SCIENTIFIC INFORMATION ......................................................................
10
PHARMACEUTICAL INFORMATION
........................................................